Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Mar 18;64(10):1462–1466. doi: 10.1136/ard.2004.033472

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab

X Baraliakos 1, J Listing 1, M Rudwaleit 1, J Brandt 1, J Sieper 1, J Braun 1
PMCID: PMC1755223  PMID: 15778240

Abstract

Background: Anti-tumour necrosis factor (TNF) treatment is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by magnetic resonance imaging. It is unclear whether anti-TNF treatment affects chronic spinal changes in AS.

Objectives: To analyse the effect of infliximab on the radiographic course of AS over 2 years.

Methods: Complete sets of lateral radiographs of the cervical spine and lumbar spine were available from 82 patients from two sources: 41 patients (group 1) had been treated with infliximab (5 mg/kg/6 weeks) as part of a recent randomised controlled trial and 41 patients (group 2) were part of the early German AS cohort (GESPIC), without controlled interventions. Radiographs were obtained at baseline and after 2 years and scored by the modified Stokes AS Spinal Score (mSASSS).

Results: Patients in the infliximab group were older, had a longer disease duration, and more radiographic damage at baseline. The mean (SD) mSASSS change was 0.4 (2.7) and 0.7 (2.8) for groups 1 and 2, respectively (p = NS). Radiographic damage at baseline was a predictor for more radiographic progression. Patients with baseline damage who were treated with infliximab showed a trend for less radiographic progression. No correlations between clinical parameters and radiographic progression were found.

Conclusions: Patients with AS treated with infliximab had less radiographic progression after 2 years. Patients with prevalent radiographic damage are prone to develop more damage over time. Infliximab may decelerate radiographic progression in such patients. Larger studies are needed to prove that anti-TNF treatment inhibits structural damage.

Full Text

The Full Text of this article is available as a PDF (124.8 KB).

Figure 1.

Figure 1

Open in a new tab

 The mSASSS. Chronic spinal changes are assessed by scoring the anterior vertebral edge of each vertebra between the lower edge of C2 and the upper edge of Th1, and between the lower edge of Th12 and the upper edge of S1.

Figure 2.

Figure 2

Open in a new tab

 Comparison of the mean radiographic progression over the 2 year study period for all patients in the two assessed groups.

Figure 3.

Figure 3

Open in a new tab

 Example of a patient with radiographic progression. Erosion and sclerosis worsened to bridging syndesmophytes after 2 years.

Figure 4.

Figure 4

Open in a new tab

 Comparison of the mean radiographic progression over the 2 year study period for patients with definite radiographic damage at baseline in the two assessed groups.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Averns H. L., Oxtoby J., Taylor H. G., Jones P. W., Dziedzic K., Dawes P. T. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol. 1996 Apr;35(4):373–376. doi: 10.1093/rheumatology/35.4.373. [DOI] [PubMed] [Google Scholar]
  2. Baraliakos X., Landewé R., Hermann K-G, Listing J., Golder W., Brandt J., Rudwaleit M., Bollow M., Sieper J., van der Heijde D. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis. 2004 Sep 30;64(5):730–734. doi: 10.1136/ard.2004.029298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Braun J., Baraliakos X., Brandt J., Listing J., Zink A., Alten R., Burmester G., Gromnica-Ihle E., Kellner H., Schneider M. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005 Mar 9;44(5):670–676. doi: 10.1093/rheumatology/keh584. [DOI] [PubMed] [Google Scholar]
  4. Braun J., Baraliakos X., Golder W., Brandt J., Rudwaleit M., Listing J., Bollow M., Sieper J., Van Der Heijde D. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003 Apr;48(4):1126–1136. doi: 10.1002/art.10883. [DOI] [PubMed] [Google Scholar]
  5. Braun J., Baraliakos X., Golder W., Hermann K-G, Listing J., Brandt J., Rudwaleit M., Zuehlsdorf S., Bollow M., Sieper J. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis. 2004 Apr 5;63(9):1046–1055. doi: 10.1136/ard.2003.019968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  7. Braun J., Bollow M., Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):697–735. doi: 10.1016/s0889-857x(05)70038-7. [DOI] [PubMed] [Google Scholar]
  8. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., Golder W., Gromnica-Ihle E., Kellner H., Schneider M. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003 Aug;48(8):2224–2233. doi: 10.1002/art.11104. [DOI] [PubMed] [Google Scholar]
  9. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., Gromnica-Ihle E., Kellner H., Schneider M., Sörensen H. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2004 Sep 23;64(2):229–234. doi: 10.1136/ard.2004.025130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  11. Braun J., Sieper J. Inzeptionskohorte für Spondylarthropathien. Z Rheumatol. 2000 Apr;59(2):117–121. doi: 10.1007/s003930050215. [DOI] [PubMed] [Google Scholar]
  12. Braun J., Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996 Jul;8(4):275–287. doi: 10.1097/00002281-199607000-00003. [DOI] [PubMed] [Google Scholar]
  13. Creemers M. C. W., Franssen M. J. A. M., van't Hof M. A., Gribnau F. W. J., van de Putte L. B. A., van Riel P. L. C. M. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2004 Mar 29;64(1):127–129. doi: 10.1136/ard.2004.020503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Creemers M. C. W., Franssen M. J. A. M., van't Hof M. A., Gribnau F. W. J., van de Putte L. B. A., van Riel P. L. C. M. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2004 Mar 29;64(1):127–129. doi: 10.1136/ard.2004.020503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed] [Google Scholar]
  16. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  17. Mullighan C. G., Heatley S., Lester S., Rischmueller M., Gordon T. P., Bardy P. G. Fas gene promoter polymorphisms in primary Sjögren's syndrome. Ann Rheum Dis. 2004 Jan;63(1):98–101. doi: 10.1136/ard.2003.006056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Taylor H. G., Beswick E. J., Dawes P. T. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol. 1991 Mar;10(1):43–48. doi: 10.1007/BF02208032. [DOI] [PubMed] [Google Scholar]
  19. Wanders Astrid J. B., Landewé Robert B. M., Spoorenberg Anneke, Dougados Maxime, van der Linden Sjef, Mielants Herman, van der Tempel Hille, van der Heijde Désirée M. F. M. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum. 2004 Aug;50(8):2622–2632. doi: 10.1002/art.20446. [DOI] [PubMed] [Google Scholar]
  20. van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361–368. doi: 10.1002/art.1780270401. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES